Investment analysts at StockNews.com assumed coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the basic materials company’s stock.
A number of other equities research analysts have also recently weighed in on the company. HC Wainwright dropped their price target on Arcadia Biosciences from $10.00 to $6.00 and set a “buy” rating for the company in a report on Thursday, May 23rd. Lake Street Capital raised Arcadia Biosciences to a “strong-buy” rating in a report on Tuesday, May 14th.
Get Our Latest Stock Analysis on Arcadia Biosciences
Arcadia Biosciences Trading Up 0.3 %
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The basic materials company reported ($1.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.52) by $0.74. Arcadia Biosciences had a negative return on equity of 84.27% and a negative net margin of 129.74%. The firm had revenue of $1.26 million during the quarter, compared to analysts’ expectations of $1.20 million. During the same period last year, the firm posted ($3.83) EPS. On average, sell-side analysts forecast that Arcadia Biosciences will post -2.29 EPS for the current fiscal year.
About Arcadia Biosciences
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Recommended Stories
- Five stocks we like better than Arcadia Biosciences
- What is Forex and How Does it Work?
- Micron Technology Stock Volatile Despite Analyst Upgrades
- How to Calculate Options Profits
- McDonald’s Stock: Balancing Value and Innovation
- What Are Dividends? Buy the Best Dividend Stocks
- MarketBeat Week in Review – 6/17 – 6/21
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.